Amplifying cancer chemoimmunotherapy through F4/80 + CD11c + DC-like macrophages induced by micellar docetaxel together with a TLR7/8 nanoagonist

Jinrong Peng,Qian Yang,Hong Jiang,Yue Wang,Qingya Liu,Yao Xiao,Zhiyong Qian

DOI: https://doi.org/10.1016/j.nantod.2023.102087

IF: 17.4

2023-12-04

Nano Today

Abstract:Chemotherapy-based combinational immunomodulation has been developed to inflame the "cold" tumor immune microenvironment (TiME) for enhanced triple-negative breast cancer (TNBC) chemoimmunotherapy. However, the potential of docetaxel-based chemotherapy combined with immunomodulation by TLR7/8 agonists remains undiscovered. Herein, we first constructed micellar docetaxel (DTX-m) and a TLR7/8 nanoagonist suitable for systematic administration, R848 nanoparticles (R848 NPs). By adjusting the administration sequence, the combination of DTX-m and R848 NPs can efficiently inhibit tumor growth in vivo in a rodent triple-negative breast cancer model. The results of a mechanistic study reveal that alternate sequential administration promotes the polarization of macrophages to F4/80 + CD11c + DC-like macrophages and cumulatively promotes the secretion of CXCL10 and proinflammatory cytokines , which boost the recruitment of NK cells and APCs to reinflame the tumor immune microenvironment, further facilitating the recruitment and proliferation of effector T cells and amplifying tumor chemoimmunotherapy. Administration sequence regulates the therapeutic outcome by steering the polarization of macrophage phenotypes.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry